Abstract Details

Title Safety of Alemtuzumab After Exposure to Chemotherapeutic Agents in Patients with Multiple Sclerosis - Experience of a single MS center

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 367

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Daniela A. Pimentel Maldonado, MD, MSCR (U.S. Food and Drug Administration) PRESENTER	Dr. Pimentel Maldonado has nothing to disclose.
Oleg Y. Yerstein, MD (Lahey Hospital & Medical Center)	Dr. Yerstein has nothing to disclose.
	No disclosure on file
Raffaella Umeton, MD	Dr. Umeton has nothing to disclose.
	No disclosure on file
Carolina Ionete, MD (UMass Memorial)	Dr. Ionete has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Ionete has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Ionete has received research support from Genetech. The institution of Dr. Ionete has received research support from Biogen. The institution of Dr. Ionete has received research support from NIH.